132 related articles for article (PubMed ID: 34125517)
1. A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.
Wu X; Zhang X; Feng W; Feng H; Ding Z; Zhao Q; Li X; Tang N; Zhang P; Li J; Wang J
ACS Appl Mater Interfaces; 2021 Jun; 13(24):27920-27933. PubMed ID: 34125517
[TBL] [Abstract][Full Text] [Related]
2. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
4. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
5. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
Xu W; Lou Y; Chen W; Kang Y
Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
[TBL] [Abstract][Full Text] [Related]
6. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
7. Zeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies.
Wu W; Yu X; Sun J; Han Y; Ma Y; Zhang G; Ma Q; Li Q; Xiang H
Int J Nanomedicine; 2023; 18():7985-7999. PubMed ID: 38164268
[TBL] [Abstract][Full Text] [Related]
8. A γ-cyclodextrin-based metal-organic framework embedded with graphene quantum dots and modified with PEGMA via SI-ATRP for anticancer drug delivery and therapy.
Jia Q; Li Z; Guo C; Huang X; Song Y; Zhou N; Wang M; Zhang Z; He L; Du M
Nanoscale; 2019 Nov; 11(43):20956-20967. PubMed ID: 31660562
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
10. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
11. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
Wang L; Wang W; Rui Z; Zhou D
Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
[TBL] [Abstract][Full Text] [Related]
12. Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.
Rudnick-Glick S; Corem-Salkmon E; Grinberg I; Margel S
J Nanobiotechnology; 2016 Dec; 14(1):80. PubMed ID: 27919267
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Sensitive Biodegradable Nanoparticles of Molecularly Imprinted Polymer-Stabilized Fluorescent Zeolitic Imidazolate Framework-8 for Targeted Imaging and Drug Delivery.
Qin YT; Feng YS; Ma YJ; He XW; Li WY; Zhang YK
ACS Appl Mater Interfaces; 2020 Jun; 12(22):24585-24598. PubMed ID: 32390415
[TBL] [Abstract][Full Text] [Related]
14. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
15. One-Pot Preparation of Peptide-Doped Metal-Amino Acid Framework for General Encapsulation and Targeted Delivery.
Mugaka BP; Zhang S; Li RQ; Ma Y; Wang B; Hong J; Hu YH; Ding Y; Xia XH
ACS Appl Mater Interfaces; 2021 Mar; 13(9):11195-11204. PubMed ID: 33645961
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases.
Xue X; Yu J; Lu F; Jiang H; Wang X
Drug Des Devel Ther; 2021; 15():4455-4468. PubMed ID: 34737552
[TBL] [Abstract][Full Text] [Related]
17. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model.
Tan ML; Friedhuber AM; Dunstan DE; Choong PF; Dass CR
Biomaterials; 2010 Jan; 31(3):541-51. PubMed ID: 19836833
[TBL] [Abstract][Full Text] [Related]
18. MOF-derived novel porous Fe
Xiang Z; Qi Y; Lu Y; Hu Z; Wang X; Jia W; Hu J; Ji J; Lu W
J Mater Chem B; 2020 Sep; 8(37):8671-8683. PubMed ID: 32856668
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
20. Cu (II)-porphyrin metal-organic framework/graphene oxide: synthesis, characterization, and application as a pH-responsive drug carrier for breast cancer treatment.
Gharehdaghi Z; Rahimi R; Naghib SM; Molaabasi F
J Biol Inorg Chem; 2021 Sep; 26(6):689-704. PubMed ID: 34420089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
